5-氟尿嘧啶联合表观遗传调节剂诱导NET细胞放射增敏及SSTR2表达与放射性配体结合
该体外前临床研究探讨5-氟尿嘧啶单用或联合DNA甲基转移酶抑制剂地西他滨或组蛋白去乙酰化酶抑制剂他西地林对神经内分泌肿瘤细胞系BON1和QGP1的影响。结果显示联合处理降低细胞活力、诱导凋亡、增强放射敏感性、上调SSTR2表达并增加68Ga-DOTATOC的放射性配体结合。提示5-氟尿嘧啶联合表观遗传调节剂可能改善肽受体化学放射核素治疗的疗效。
要点
- 5-氟尿嘧啶单用或联合地西他滨/他西地林增强NET细胞放射敏感性。
- 联合处理上调SSTR2表达并增加68Ga-DOTATOC放射性配体结合。
- 提示该联合策略可能提升NET肽受体化学放射核素治疗疗效。
核心结论
- 5-氟尿嘧啶单用或联合地西他滨或他西地林可诱导NET细胞放射增敏、上调SSTR2表达并增加68Ga-DOTATOC结合。
研究设计与样本
- 体外前临床研究,使用人NET细胞系BON1和QGP1。
- 5-氟尿嘧啶单用或分别联合地西他滨或他西地林处理细胞。
- 采用集落形成实验检测联合0、2、4或6 Gy γ射线照射后的放射敏感性。
- 采用Western blot和放射性配体结合实验检测SSTR2表达及68Ga-DOTATOC摄取。
主要发现
- 5-氟尿嘧啶单用或联合地西他滨或他西地林降低BON1和QGP1细胞活力并诱导凋亡。
- 联合处理增强BON1和QGP1细胞的放射敏感性。
- 联合处理诱导SSTR2表达并增加NET细胞对68Ga-DOTATOC的放射性配体结合。
关键数值与推荐
- γ射线照射剂量为0、2、4或6 Gy。
- 检测指标包括细胞活力、凋亡、集落形成、SSTR2蛋白表达及68Ga-DOTATOC放射性配体结合。
临床怎么用
- 提示5-氟尿嘧啶联合表观遗传调节剂可能作为提高NET肽受体化学放射核素治疗疗效的候选策略。
- SSTR2表达上调及68Ga-DOTATOC结合增加提示该联合可能改善放射性配体治疗靶向性。
局限性
- 本研究为体外前临床研究,结论需进一步体内及临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peptide receptor radionuclide therapy in advanced neuroendocrine tumors (NETs) demonstrates a limited objective response rate. The therapeutic efficacy might be further increased by peptide receptor chemoradionuclide therapy. In this preclinical study, we explored the effects of 5-fluorouracil plus the DNA methyltransferase inhibitor decitabine or the histone deacetylase inhibitor tacedinaline on NET cells in vitro. Methods: Human NET cell lines BON1 and QGP1 were treated with 5-fluorouracil alone or in combination with decitabine or tacedinaline, respectively. Radiosensitivity was tested in combination with γ-irradiation at doses of 0, 2, 4, or 6 Gy by colony formation assay. Somatostatin receptor type 2 (SSTR2) expression and 68Ga-DOTATOC uptake by human NET cell lines were investigated by Western blot analysis and by a radioligand binding assay. Results: Treatment with 5-fluorouracil alone or in combination with decitabine or tacedinaline reduced tumor cell viability and induced apoptosis, enhanced radiosensitivity in BON1 and QGP1 cells, induced SSTR2 expression, and resulted in increased radioligand binding of 68Ga-DOTATOC in NET cells. Conclusion: This preclinical study demonstrated that 5-fluorouracil alone or in combination with decitabine or tacedinaline caused radiosensitization of tumor cells, upregulation of SSTR2 expression in tumor cells, and increased radioligand binding of 68Ga-DOTATOC to these tumor cells. These preclinical in vitro findings indicate that 5-fluorouracil in combination with epigenetic modifiers might be a putative strategy to improve the treatment efficacy of peptide receptor chemoradionuclide therapy in NET.
引用
- Jin XF, Auernhammer CJ, Ilhan H, et al. Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro. J Nucl Med. 2019. PMID: 30796167. doi:10.2967/jnumed.118.224048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。